TY - JOUR
T1 - Factor structure of cognitive performance and functional capacity in schizophrenia
T2 - Evidence for differences across functional capacity measures
AU - Harvey, Philip D.
AU - Horan, William P.
AU - Atkins, Alexandra S.
AU - Stevens, Heather
AU - Welch, Matthew
AU - Yuan, Joshua
AU - Patterson, Thomas L.
AU - Narasimhan, Meera
AU - Keefe, Richard S.E.
N1 - Funding Information:
In the last year, Dr. Harvey has received investigator-initiated research funding support from the Department of Veterans Affairs, the National Institute of Aging, the U.S. Department of Veterans Affairs, and the National Institute of Mental Health. He has received consulting fees or travel reimbursements from Alkermes, BioExcel, Boehringer Ingelheim, Intra-Cellular Therapies, Minerva Pharma, Otsuka America, Regeneron, Roche Pharma, and Sunovion Pharma. He receives royalties from the Brief Assessment of Cognition in Schizophrenia and the MATRICS Consensus Battery. He has a research grant from Takeda and from the Stanley Medical Research Foundation. He is chief Scientific Officer of iFunction, Inc.None. This study was supported by Funding was provided by the National Institute of Mental Health Grant Numbers 1R43MH084240-01A2 and 2R44MH084240-02.
Funding Information:
In the last year, Dr. Harvey has received investigator-initiated research funding support from the Department of Veterans Affairs , the National Institute of Aging , the U.S. Department of Veterans Affairs , and the National Institute of Mental Health . He has received consulting fees or travel reimbursements from Alkermes, BioExcel, Boehringer Ingelheim, Intra-Cellular Therapies, Minerva Pharma, Otsuka America, Regeneron, Roche Pharma, and Sunovion Pharma. He receives royalties from the Brief Assessment of Cognition in Schizophrenia and the MATRICS Consensus Battery. He has a research grant from Takeda and from the Stanley Medical Research Foundation. He is chief Scientific Officer of iFunction, Inc.
Funding Information:
This study was supported by Funding was provided by the National Institute of Mental Health Grant Numbers 1R43MH084240-01A2 and 2R44MH084240-02 .
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/9
Y1 - 2020/9
N2 - Background: Cognition and functional capacity predict functional outcomes in mental illness. Traditional approaches conceptualize cognition as comprised of domains, but many studies support a unifactorial structure. Some functional capacity measures may share a single-factor structure with cognition. In this study, we examined the factor structure of two measures of functional capacity, a conventional assessment and a newer computerized assessment, testing for a shared factor structure with cognition. Methods: Patients with schizophrenia and healthy controls were examined with the MATRICS Consensus Cognitive Battery (MCCB), the UCSD Performance Based Skills Assessment (UPSA), and the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). Models of the factor structures of the MCCB, UPSA, and VRFCAT were calculated, as were correlations between MCCB scores and individual VRFCAT objectives. Results: The MCCB, VRFCAT, and UPSA all had unifactorial structures. The best fitting model of the correlations between MCCB and UPSA was a shared single factor, while the best fit for the relationship between MCCB and VRFCAT had two factors. Correlations between the MCCB domain and composite scores and the VRFCAT objectives suggested global rather than specific patterns of correlation. Discussion: The relationship between cognitive performance and functional capacity was found to vary across functional capacity assessments. The UPSA and MCCB were not differentiated into separate factors, suggesting that the UPSA may overlap with neurocognitive performance. However, the VRFCAT appears to measure functional abilities that are separable from, yet correlated with, neurocognitive performance. It may provide a more distinctive assessment of the functional capacity construct.
AB - Background: Cognition and functional capacity predict functional outcomes in mental illness. Traditional approaches conceptualize cognition as comprised of domains, but many studies support a unifactorial structure. Some functional capacity measures may share a single-factor structure with cognition. In this study, we examined the factor structure of two measures of functional capacity, a conventional assessment and a newer computerized assessment, testing for a shared factor structure with cognition. Methods: Patients with schizophrenia and healthy controls were examined with the MATRICS Consensus Cognitive Battery (MCCB), the UCSD Performance Based Skills Assessment (UPSA), and the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). Models of the factor structures of the MCCB, UPSA, and VRFCAT were calculated, as were correlations between MCCB scores and individual VRFCAT objectives. Results: The MCCB, VRFCAT, and UPSA all had unifactorial structures. The best fitting model of the correlations between MCCB and UPSA was a shared single factor, while the best fit for the relationship between MCCB and VRFCAT had two factors. Correlations between the MCCB domain and composite scores and the VRFCAT objectives suggested global rather than specific patterns of correlation. Discussion: The relationship between cognitive performance and functional capacity was found to vary across functional capacity assessments. The UPSA and MCCB were not differentiated into separate factors, suggesting that the UPSA may overlap with neurocognitive performance. However, the VRFCAT appears to measure functional abilities that are separable from, yet correlated with, neurocognitive performance. It may provide a more distinctive assessment of the functional capacity construct.
KW - Functional capacity
KW - Neurocognition
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85090712723&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090712723&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2020.08.010
DO - 10.1016/j.schres.2020.08.010
M3 - Article
C2 - 32928621
AN - SCOPUS:85090712723
VL - 223
SP - 297
EP - 304
JO - Schizophrenia Research
JF - Schizophrenia Research
SN - 0920-9964
ER -